Can a spinal pump deliver better pain relief for pancreatic cancer?

NCT ID NCT07733427

First seen Jul 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical painkillers. Researchers will track pain levels, opioid use, quality of life, sleep, and safety over 12 months to see if this approach offers meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
intrathecal analgesia via an implantable pump delivering pain medication directly to the spinal cord
What this could lead to
If effective, this approach could offer a new way to control severe pancreatic cancer pain that does not respond to standard treatments, potentially reducing opioid use and improving quality of life.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply broadly. The procedure carries risks such as infection, bleeding, or device malfunction, and it is unclear whether it will meaningfully reduce pain or opioid needs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRATHECAL ADMINISTRATION OF THE DRUG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Benkessou

    Paris, 75016, France

  • Bizet Clinic

    Paris, 75016, France

  • Clinique Bizet

    Paris, 75016, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.